Ampio Pharmaceuticals (NYSE:AMPE) Now Covered by

Research analysts at initiated coverage on shares of Ampio Pharmaceuticals (NYSE:AMPEGet Rating) in a research report issued to clients and investors on Sunday. The brokerage set a “sell” rating on the stock.

Ampio Pharmaceuticals Stock Performance

Ampio Pharmaceuticals Company Profile

(Get Rating)

Ampio Pharmaceuticals, Inc operates as a biopharmaceutical company. The firm engages in the development of therapies to treat prevalent inflammatory conditions. Its product pipeline includes new uses for approved drugs and new molecular entities for important therapeutic areas, including metabolic disease, eye disease, kidney disease, inflammation and sexual dysfunction and CNS disease.

Recommended Stories

Receive News & Ratings for Ampio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ampio Pharmaceuticals and related companies with's FREE daily email newsletter.